Implications of clinical research on adjuvant chemotherapy for gastric cancer: Where to go next?

作     者：Xinhua Chen Hao Liu Guoxin Li Jiang Yu 

作者机构：Department of General Surgery Nanfang Hospital Southern Medical University 

出 版 物：《Chinese Journal of Cancer Research》 (中国癌症研究（英文版）)

年 卷 期：2019年第31卷第6期

页      面：892-900页

核心收录：

学科分类：1002[医学-临床医学] 100214[医学-肿瘤学] 10[医学] 

基　　金：supported by the National Natural Science Foundation of China (No. 81872013) National Key Research and Development Program (No.2017YFC 0108300) National Key Clinical Specialty Discipline Construction Program of China (No. 121) Science and Technology Planning Project of Guangdong Province (No.2017B020226005) 

主　　题：Gastric cancer(GC) adjuvant chemotherapy(ACT) clinical trial tailored 

摘      要：Postoperative adjuvant chemotherapy(ACT)confers superior gastric cancer(GC)survival in the Eastern cohort.However,is the current standard of ACT already excessive,or is it still necessary to increase its intensity for specific subgroups?Tailored ACT strategies for GC depend on gradual exploration by clinical trials in selected patients.Thus,understanding the implications of previous and current research can help us respond wisely and design effective,rational trials,save medical resources and make better decisions in clinical practice.After reviewing and analyzing studies on ACT for GC patients undergoing curative resection,we found that research strategies for conductingadditionACT for specific stages of the disease have achieved great progress in making ACT more tailored and personalized in consideration of pathology stages.Furthermore,trials indicate thatadditionACT strategies for GC patient subgroups based on histological characteristics might be helpful to move toward a more specific tailored and personalized management approach.Designing ACT research focused on different node statuses should also be conducted according to the biological specificity of lymph node(LN)metastasis.Therefore,future trials designed to determine tailored treatment based on histological and biological characteristics for specific subgroups are urgently needed and conducted as the theme of the 2019 American Society of Clinical Oncology(ASCO):Caring for Every Patient,Learning from Every Patient.